Max Healthcare Institute Ltd has received an Outperform rating from CLSA, which set a target price of INR1,025. The brokerage highlighted the company's strong presence in metropolitan areas, effective cost optimization strategies, and ambitious capacity expansion plans, positioning it for robust medium-term earnings growth. CLSA's analysis suggests that Max Healthcare's stock is expected to outperform the average return of its covered stocks, making it an attractive option for investors in the Indian healthcare sector.